Evidence map›Paper›PMID 39433911›Full record

ArticleBone marrow transplantation2025

Precision medicine results from equitable representation.

Alexandra Gomez-Arteaga, Nora Chokr, Jeffery J Auletta

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexandra Gomez-ArteagaDepartment of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine/NewYork Presbyterian Hospital, New York, NY, USA. alg9117@med.cornell.edu.ORCID 0000-0003-0897-3790
Nora ChokrDepartment of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine/NewYork Presbyterian Hospital, New York, NY, USA.ORCID 0000-0002-2275-2508
Jeffery J AulettaNMDP, Minneapolis, MN, USA.ORCID 0000-0002-1515-2141

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this special issue of Bone Marrow Transplantation, investigators report the impact of IDH1 [1], IDH2 [2], and FLT3-TKD [3] measurable residual disease (MRD) pre-hematopoietic cell transplantation (HCT) in predicting relapse of acute myeloid leukemia (AML) in adults receiving allogeneic HCT. The patient population for these retrospective cohorts, reflecting clinical transplant practice patterns and research biobank participation, was 84-86% non-Hispanic White (NHW) in each study. In this commentary, we explore the implications of racial and ethnic disparities in access to both HCT and HCT-related research and propose strategies to promote representation in precision medicine, given the emerging impact of the field on HCT outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePrecision MedicineFemaleHumans

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.